Array Announces Global Phase 3 Trial Evaluating MEK162 In Patients With Low-Grade Serous Ovarian Cancer

MEK-162: 
5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzo[d]imidazole-6-carboxamide.
May 6, 2013
Array BioPharma Inc. today announced.....read all at
 http://newdrugapprovals.wordpress.com/2013/05/10/array-announces-global-phase-3-trial-evaluating-mek162-in-patients-with-low-grade-serous-ovarian-cancer/